Revocation of Licences - Cell Care Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, addresses the regulation of therapeutic goods to ensure public health and safety. This Act empowers the Therapeutic Goods Administration to manage the import, export, manufacture, and sale of therapeutic goods within Australia. The revocation of licences under this Act serves to enforce compliance with regulatory requirements, particularly concerning the payment of annual licensing charges. The revocation of the licence for Cell Care Australia Pty Ltd, as specified in the gazette, exemplifies this enforcement mechanism, as the sponsor's failure to meet financial obligations within the stipulated timeframe resulted in the cancellation of their licence. This action underscores the policy objective of maintaining stringent regulatory standards to protect consumers and uphold the integrity of the therapeutic goods market.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad spectrum of therapeutic goods, encompassing medicines, medical devices, blood, and tissues. It governs the regulation of these goods to ensure they meet safety, quality, and efficacy standards before being made available in Australia. The Act applies to sponsors, manufacturers, importers, and suppliers of therapeutic goods, as well as to the goods themselves. Its jurisdictional reach extends across the Commonwealth, with each state and territory having corresponding legislation that aligns with the national framework, though the primary oversight and regulation are conducted by the Therapeutic Goods Administration (TGA). Exclusions and exemptions within the Act are limited and typically pertain to specific types of goods or activities, such as research and development of certain medical devices under defined conditions. The Act’s application may also be extended or restricted through subordinate instruments such as regulations and guidelines, which provide further detail on compliance and enforcement mechanisms.

Key Provisions

Under Section 41(1)(f) of the Therapeutic Goods Act 1989, the Act provides the authority to revoke a licence if the annual licensing charges are not paid within 28 days of becoming due. This legislative provision ensures that all entities holding a licence for therapeutic goods maintain their compliance with regulatory requirements by keeping their financial obligations up to date. In this instance, the revocation notice issued by Nicole McLay, as the Delegate of the Secretary to the Department of Health and Ageing, specifies that the licence held by Cell Care Australia Pty Ltd, MI-09122004-LI-000298-1, was revoked on 11 June 2013 due to the non-payment of the annual licensing charges. The Therapeutic Goods Act 1989 imposes specific obligations on entities holding licences for therapeutic goods. Primarily, these entities must ensure they meet all financial obligations, including the timely payment of annual licensing charges. Failure to do so within the stipulated 28-day period results in the automatic revocation of the licence, as seen in the case of Cell Care Australia Pty Ltd. Additionally, entities are required to maintain records and documentation that demonstrate compliance with all aspects of the Act, including financial, manufacturing, and distribution standards. The Act delineates clear consequences for entities that fail to meet their obligations. Specifically, non-payment of the annual licensing charges within the prescribed timeframe results in the revocation of the licence, as occurred with Cell Care Australia Pty Ltd. This revocation means that the entity can no longer legally manufacture, supply, or otherwise deal with the therapeutic goods covered by the revoked licence. Furthermore, while the Therapeutic Goods Act 1989 does not specify a maximum penalty for this particular offence in the revocation notice, breaches of other sections of the Act can result in substantial penalties. For instance, breaches may lead to fines of up to $220,000 for individuals and $1,100,000 for bodies corporate, as well as potential criminal charges and imprisonment. This underscores the importance of adhering to all regulatory requirements to avoid severe civil and criminal repercussions.